Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Wai-Ping Woo"'
Autor:
Rahul Ladwa, Janin Chandra, Wai-Ping Woo, Neil Finlayson, Howard Liu, Margaret McGrath, Adrienne See, Brett G. Hughes, Caroline L. Cooper, Jim E. Jackson, Marcin Dzienis, Yan Xu, Benedict Panizza, Ian Frazer, Sandro V. Porceddu
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundProgrammed cell death ligand 1 (PD-L1) inhibitors have limited efficacy as monotherapy in patients with recurrent/metastatic (R/M) Human Papilloma Virus (HPV) oropharyngeal squamous cell carcinoma (OPSCC). A phase I study of the therapeutic
Externí odkaz:
https://doaj.org/article/fb7a6deac1ce446d93ed6b6a8082e5ce
Autor:
Janin Chandra, Wai-Ping Woo, Julie L Dutton, Yan Xu, Bo Li, Sally Kinrade, Julian Druce, Neil Finlayson, Paul Griffin, Kerry J Laing, David M Koelle, Ian H Frazer
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0226320 (2019)
BackgroundGenital herpes simplex infection affects more than 500 million people worldwide. We have previously shown that COR-1, a therapeutic HSV-2 polynucleotide vaccine candidate, is safe and well tolerated in healthy subjects.ObjectiveHere, we pre
Externí odkaz:
https://doaj.org/article/6cdd6f51bde94d0c86f148aa687faacc
Autor:
Julie L Dutton, Bo Li, Wai-Ping Woo, Joshua O Marshak, Yan Xu, Meei-li Huang, Lichun Dong, Ian H Frazer, David M Koelle
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76407 (2013)
While there are a number of licensed veterinary DNA vaccines, to date, none have been licensed for use in humans. Here, we demonstrate that a novel technology designed to enhance the immunogenicity of DNA vaccines protects against lethal herpes simpl
Externí odkaz:
https://doaj.org/article/6cf7eb6dc3cb4dbda67c89bb27536c30
Autor:
Ladwa, Rahul, Chandra, Janin, Wai-Ping Woo, Finlayson, Neil, Liu, Howard, McGrath, Margaret, See, Adrienne, Hughes, Brett G., Cooper, Caroline L., Jackson, Jim E., Dzienis, Marcin, Yan Xu, Panizza, Benedict, Frazer, Ian, Porceddu, Sandro V.
Publikováno v:
Frontiers in Oncology; 2024, p1-8, 8p
Autor:
Wai-Ping Woo, Janin Chandra, Sandro V. Porceddu, Rahul Ladwa, Howard Liu, M. Brauer, Yan Xu, M. McGrath, Benedict Panizza, Ian H. Frazer, Neil Finlayson, Sarah J. Hanson
Publikováno v:
Cancer Immunology, Immunotherapy. 70:743-753
We conducted a phase 1 dose escalation study (ACTRN12618000140257 registered on 30/01/2018) to evaluate the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) in subjects previously treated for HP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6faf0bbee9c61d4dd4ab5b3ecf3ffb1
https://doi.org/10.1007/s00262-020-02720-7
https://doi.org/10.1007/s00262-020-02720-7
Autor:
Yan Xu, David M. Koelle, Sally Kinrade, Bo Li, Neil Finlayson, Janin Chandra, Julie L. Dutton, Julian Druce, Wai-Ping Woo, Kerry J. Laing, Paul M. Griffin, Ian H. Frazer
Publikováno v:
PLoS ONE, Vol 14, Iss 12, p e0226320 (2019)
PLoS ONE
PLoS ONE
BackgroundGenital herpes simplex infection affects more than 500 million people worldwide. We have previously shown that COR-1, a therapeutic HSV-2 polynucleotide vaccine candidate, is safe and well tolerated in healthy subjects.ObjectiveHere, we pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2594046013f3d691709144512c310018
https://doaj.org/article/6cdd6f51bde94d0c86f148aa687faacc
https://doaj.org/article/6cdd6f51bde94d0c86f148aa687faacc
Autor:
Janin Chandra, Bo Li, Julie L. Dutton, Wai-Ping Woo, Yan Xu, Neil Finlayson, Paul M. Griffin, Ian H. Frazer
Publikováno v:
Human Vaccines & Immunotherapeutics
This paper describes a single site, open-label Phase I clinical trial evaluating the safety, tolerability and immunogenicity in healthy volunteers of a herpes simplex polynucleotide vaccine that has previously been shown to enhance immunogenicity and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0632ec1f4c1cb658c98c05080b1da02c
https://doi.org/10.1080/21645515.2016.1221872
https://doi.org/10.1080/21645515.2016.1221872
Autor:
Janin Chandra, Lynn Tolley, Graham R. Leggatt, Julie L. Dutton, James W. Wells, Neil Finlayson, Ian H. Frazer, Yan Xu, Bo Li, Michelle K Yong, Wai-Ping Woo
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Supplemental Digital Content is available in the text.
We have previously shown that a novel DNA vaccine technology of codon optimization and the addition of ubiquitin sequences enhanced immunogenicity of a herpes simplex virus 2 polynucleotide
We have previously shown that a novel DNA vaccine technology of codon optimization and the addition of ubiquitin sequences enhanced immunogenicity of a herpes simplex virus 2 polynucleotide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ec7f5afc1ad15b5325d67db19500771
https://pubmed.ncbi.nlm.nih.gov/28166181
https://pubmed.ncbi.nlm.nih.gov/28166181
Publikováno v:
Journal of Virology. 80:3975-3984
Although hepatitis B surface antigen (HBsAg) per se is highly immunogenic, its use as a vector for the delivery of foreign cytotoxic T-lymphocyte (CTL) epitopes has met with little success because of constraints on HBsAg stability and secretion impos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38eb09b06b1cf724c094bcf160c19618
https://doi.org/10.1128/jvi.80.8.3975-3984.2006
https://doi.org/10.1128/jvi.80.8.3975-3984.2006
Publikováno v:
Vaccine. 21:2692-2697
Due to their spatial structure virus-like particles (VLPs) generally induce effective immune responses. VLPs derived from the small envelope protein (HBsAg-S) of hepatitis B virus (HBV) comprise the HBV vaccine. Modified HBsAs-S VLPs, carrying the im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1533dc79f5561ea0b0f934e9c56e4be5
https://doi.org/10.1016/s0264-410x(03)00182-8
https://doi.org/10.1016/s0264-410x(03)00182-8